PMID- 33126251
OWN - NLM
STAT- MEDLINE
DCOM- 20210503
LR  - 20230216
IS  - 2156-5376 (Electronic)
IS  - 2161-8313 (Print)
IS  - 2161-8313 (Linking)
VI  - 12
IP  - 2
DP  - 2021 Mar 31
TI  - Perspective: Prospects for Nutraceutical Support of Intestinal Barrier Function.
PG  - 316-324
LID - 10.1093/advances/nmaa139 [doi]
AB  - Impairment of intestinal barrier function is linked to certain pathologies and to 
      aging, and can be a cause of bacterial infections, systemic and hepatic 
      inflammation, food allergies, and autoimmune disorders. The formation and 
      maintenance of intestinal tight junctions is supported by glucagon-like peptide-2 
      (GLP-2), which via insulin-like growth factor I activity boosts phosphoinositide 
      3-kinase/Akt/mammalian target of rapamycin complex 1 (PI3K/Akt/mTORC1) signaling 
      in enterocytes. 5'-AMP-activated protein kinase (AMPK) activity as well as 
      estrogen receptor-beta (ERbeta) activity are also protective in this regard. 
      Conversely, activation of mitogen-activated protein kinases (MAPKs) and cellular 
      Src (c-Src) under inflammatory conditions can induce dissociation of tight 
      junctions. Hence, nutraceuticals that promote GLP-2 secretion from L 
      cells-effective pre/probiotics, glycine, and glutamine-as well as diets rich in 
      soluble fiber or resistant starch, can support intestinal barrier function. AMPK 
      activators-notably berberine and the butyric acid produced by health-promoting 
      microflora-are also beneficial in this regard, as are soy isoflavones, which 
      function as selective agonists for ERbeta. The adverse impact of MAPK and c-Src 
      overactivation on the intestinal barrier can be combatted with various 
      antioxidant measures, including phycocyanobilin, phase 2-inducer nutraceuticals, 
      and N-acetylcysteine. These considerations suggest that rationally designed 
      functional foods or complex supplementation programs could have clinical 
      potential for supporting and restoring healthful intestinal barrier function.
CI  - (c) The Author(s) 2020. Published by Oxford University Press on behalf of the 
      American Society for Nutrition.
FAU - McCarty, Mark F
AU  - McCarty MF
AD  - Catalytic Longevity, San Diego, CA, USA.
FAU - Lerner, Aaron
AU  - Lerner A
AD  - Chaim Sheba Medical Center, Zabludowicz Center for Autoimmune Diseases, 
      Tel-Hashomer, Israel.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Adv Nutr
JT  - Advances in nutrition (Bethesda, Md.)
JID - 101540874
SB  - IM
MH  - Dietary Supplements
MH  - Humans
MH  - *Intestinal Mucosa
MH  - *Phosphatidylinositol 3-Kinases
MH  - Signal Transduction
MH  - Tight Junctions
PMC - PMC8243597
OTO - NOTNLM
OT  - N-acetylcysteine
OT  - AMPK
OT  - berberine
OT  - butyric acid
OT  - glucagon-like peptide 2
OT  - intestinal barrier
OT  - intestinal permeability
OT  - nutraceuticals
OT  - phycocyanobilin
OT  - tight junction
EDAT- 2020/10/31 06:00
MHDA- 2021/05/04 06:00
PMCR- 2021/10/30
CRDT- 2020/10/30 20:16
PHST- 2020/07/23 00:00 [received]
PHST- 2020/08/28 00:00 [revised]
PHST- 2020/09/24 00:00 [accepted]
PHST- 2020/10/31 06:00 [pubmed]
PHST- 2021/05/04 06:00 [medline]
PHST- 2020/10/30 20:16 [entrez]
PHST- 2021/10/30 00:00 [pmc-release]
AID - S2161-8313(22)00186-7 [pii]
AID - nmaa139 [pii]
AID - 10.1093/advances/nmaa139 [doi]
PST - ppublish
SO  - Adv Nutr. 2021 Mar 31;12(2):316-324. doi: 10.1093/advances/nmaa139.